Tvardi Cash Reserves at $30.8M, Sufficient to Fund Operations Through Q4 2026
Cash, cash equivalents and short-term investments as of December 31, 2025, were $30.8M, as compared to $31.6M as of December 31, 2024. Tvardi anticipates that its current cash runway is sufficient to fund operations, as currently planned, through clinical readouts and into the fourth quarter of 2026. Imran Alibhai, CEO of Tvardi, stated, "We entered 2026 with line-of-site to two significant clinical milestones: 1) healthy volunteer data from our next-generation STAT3 inhibitor, TTI-109, in the second quarter of this year, and 2) topline data from our ongoing Phase 2 trial of TTI-101 in HCC, which we anticipate in the second half."
